Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Globe Newswire•09/10/2026•08:00 ET
0
Key Highlights
- ➤IRulya Therapeutics replaces Quince Therapeutics; Nasdaq ticker changes to IRLA October 12, 2026
- ➤Cash balance $116 million expected to fund operations through end of 2028
- ➤LAM-001 Phase 2b PH-ILD data anticipated in first quarter of 2028
- ➤LAM-001 BOS Phase 2 data anticipated in first quarter of 2027
- ➤IRulya plans to initiate LAM-001 Phase 2 SAPH study in 4Q26
Expert Statements
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
“Today marks an important milestone as we introduce our newly transformed company as IRulya Therapeutics”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
“With a focus on the clinical development of LAM-001, a potentially first in class, one puff once daily dry powder inhaled (DPI) formulation of rapamycin, we believe we have an opportunity to change the current treatment paradigm for serious pulmonary diseases.”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
“Importantly, our strengthened balance sheet positions us well to advance LAM-001 through data readouts across Phase 2 clinical studies in three pulmonary indications: BOS, PH-ILD, and SAPH.”
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026
Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D.
Get started
Create a free account to read the full story.